All In Biotech

Drug Trial Radar · NCT02768363

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

187

Actual

Start

May 2016

Primary completion

Nov 2024

Study completion Dec 2026

Sponsor

Lead sponsor
Candel Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. CAN-2409 has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that CAN-2409 can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the CAN-2409 or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance evaluations.

Conditions

  • Prostate Cancer

Interventions

  • aglatimagene besadenovecBiological

    Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.

  • placeboBiological

    Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.

  • valacyclovirDrug

    Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Baseline to study completion, approximately 5 years

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Foothills Urology

    Golden, Colorado

  • Jesse Brown VA Medical Center

    Chicago, Illinois

  • The University of Chicago

    Chicago, Illinois

  • Southeast Louisiana Veterans Health Care System

    New Orleans, Louisiana

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Kansas City VA Medical Center

    Kansas City, Missouri

  • Sierra Nevada Health Care System VA

    Reno, Nevada

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Advanced Radiation Centers of New York (Integrated Medical Professionals)

    North Hills, New York

  • Associated Medical Professionals of NY, PLLC

    Syracuse, New York

  • Southwest Urology, Clinical Research Solutions

    Middleburg Heights, Ohio

  • Oklahoma City VA Healthcare System

    Oklahoma City, Oklahoma

  • VA Portland Health Care System

    Portland, Oregon

  • Oregon Urology Insitute

    Springfield, Oregon

  • Lancaster Urology

    Lancaster, Pennsylvania

  • Allegheny Health Network-Triangle Urological Group

    Pittsburgh, Pennsylvania

  • Ralph H. Johnson Veterans Affairs Medical Center

    Charleston, South Carolina

  • San Antonio VA Healthcare System

    San Antonio, Texas

  • Woodland Center

    The Woodlands, Texas

  • Texas Urology Specialists

    Tomball, Texas

  • Hunter Holmes McGuire VA Medical Center

    Richmond, Virginia

  • Salem VA Medical Center

    Salem, Virginia

  • Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Subirán

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.